Zai Lab’s H1 2026: Revenue Slips 6%, Net Loss Deepens 14% as Licensing Spend Rises

Bulletin Express
Yesterday

Zai Lab reported a net loss of USD 101.84 million for the six months ended 30 June 2026, widening 14% year on year, as a higher research and development bill offset resilient product launches.

Net product revenue retreated 6% to USD 201.31 million. A 31% slide in ovarian-cancer therapy Zejula sales (USD 62.05 million) and a 7% drop in Vyvgart/Vyvgart Hytrulo (USD 41.42 million) overshadowed strong gains from hospital-acquired infection treatment Xacduro, which almost tripled to USD 16.53 million, and antibiotic Nuzyra, up 13% to USD 33.36 million. Collaboration revenue more than doubled to USD 4.62 million.

Cost of product revenue increased 6% to USD 86.48 million, trimming gross margin, while research and development expenses climbed 14% to USD 127.36 million on higher licensing fees, including a USD 8.00 million payment tied to MediLink’s DLL3-targeting ADC and USD 29.00 million across other partnerships. Selling, general and administrative costs edged up 3% to USD 137.94 million, reflecting ongoing commercial support.

Basic and diluted loss per share widened to USD 0.09 from USD 0.08 a year earlier.

Liquidity remained solid with USD 718.64 million in cash, cash equivalents, restricted cash and short-term investments at period-end, against USD 238.10 million in short-term debt. The gearing ratio rose to 39% from 29% at year-end 2025.

Key pipeline and commercial milestones included: • China launch of KarXT, the first schizophrenia therapy with a novel M1/M4 mechanism in more than 70 years. • China NMPA approval of antibody-drug conjugate TIVDAK for recurrent or metastatic cervical cancer following chemotherapy. • Presentation of positive Phase 1 data for DLL3-targeting ADC zocilurtatug pelitecan (Zoci) in small-cell lung cancer and extrapulmonary NECs; FDA Fast Track designation and EMA/FDA orphan drug designations secured. • New global collaborations with Amgen and Boehringer Ingelheim to study Zoci in combination regimens. • Participation in successful global Phase 3 studies for efgartigimod (Vyvgart) in ocular MG and autoimmune myositis, and for povetacicept in IgA nephropathy. • Regulatory filing in China for Optune TTFields in pancreatic cancer following FDA approval.

Headcount rose to 1,871 from 1,797 at end-2025, while total remuneration costs slipped to USD 127.0 million. No interim dividend was declared.

Zai Lab affirmed its three-pillar strategy of accelerating medicines to patients, expanding its pipeline through internal R&D and partnerships, and pursuing commercial execution to progress toward profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10